- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03106571
Study of Pomaglumetad and Methamphetamine (POMA-MA-Ph1)
Phase 1 Safety-interaction Study of Pomaglumetad Methionil for Methamphetamine Use Disorder
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study design is a randomized, double-blind, placebo-controlled multiple ascending-dose study of pomaglumetad in 24 non-treatment seeking participants with methamphetamine use disorder. Three cohorts of 8 participants each (total N = 24) will be enrolled and within each cohort participants will be randomly assigned in a 6:2 ratio to undergo methamphetamine infusions and assessments during treatment with pomaglumetad (N = 6 per cohort) or placebo (N = 2 per cohort). Participants in cohort 1 will receive pomaglumetad 40 mg orally twice daily (BID) or placebo, cohort 2 will receive pomaglumetad 80 mg BID or placebo, and cohort 3 will receive pomaglumetad 160 mg BID or placebo.
After completing outpatient baseline and screening/eligibility assessments, eligible participants will be admitted to the UCLA Hospital and will remain hospitalized during all experimental procedures (approximately 11 days and 10 nights).
A urine drug toxicology screen free of illicit substances (with the exception of THC) is required for admission. Upon admission, participants will receive a sample/test infusion of MA 30 mg IV. Participants tolerating the test infusion (no serious adverse advents and not exceeding stopping criteria below) will be randomized to receive POMA (40 mg BID in cohort 1, 80 mg BID in cohort 2, and 160 mg BID in cohort 3) or placebo.
Following three days of MA abstinence and POMA/placebo dosing to achieve study medication steady-state, participants will complete a MA self-administration session.
After two days for MA washout, participants will then have serial plasma samples collected over 12 hours to assess PK for POMA. The next day, participants will receive a 30 mg MA infusion followed by serial plasma sample collection over the following 48 hours for MA PK analysis.
Measures of cardiovascular response, subjective effects, and adverse events will be assessed following all MA infusions during self-administration and PK sessions.
Upon completion of the PK sample collection, participants will be discharged and a 14-day post-discharge (± 7 days) follow-up outpatient visit will be completed for safety purposes.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Santa Monica, California, United States, 90404
- UCLA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- not seeking treatment for MA problems at the time of the study;
- English-speaking;
- age 18-55 years inclusive;
- meet DSM-5 criteria for MA use disorder, moderate-severe as diagnosed via MINI;
- have a self-reported history of using MA either via injection or smoking and provide at least one MA-positive urine prior to admission;
- provide a urine drug screen negative for all illicit drugs, excepting THC, on the day of scheduled inpatient admission;
- report methamphetamine use on 10 or more days in the past 30 days at baseline;
- have a resting heart rate ≤ 100 bpm, systolic blood pressure ≤ 160 mm Hg, and diastolic blood pressure ≤ 100 mm Hg prior to admission;
- have a baseline EKG that demonstrates normal sinus rhythm, QTc ≤ 450 msec in men or QTc ≤ 460 msec in women, and no clinically significant arrhythmias;
- if female (except females of non-childbearing potential-e.g., at least 1 year post-menopausal or surgically sterile), not pregnant confirmed by negative pregnancy test nor lactating and willing to use a medically approved method of birth control to prevent pregnancy during the trial and for 40 days after the last dose of study medication;
- if male, willing to refrain from donating sperm during the study and for 100 days following the last dose of study medication and agree that they and their partners will use a medically approved contraceptive method;
- have a medical history and physical/neurological examination demonstrating no additional clinically significant contraindications for study participation, in the judgment of the investigators;
- able to participate in all scheduled evaluations, likely to complete all scheduled tests, and likely to be adherent, in the opinion of the investigator and;
- agree not to post any personal medical data or information related to the study on any social media site or website until the trial has completed.
Exclusion Criteria:
- non-English speaking;
- currently on probation or parole;
- have current cocaine, opioid, marijuana, or alcohol use disorder, moderate-severe;
- have liver function tests (total bilirubin, ALT, AST, or alkaline phosphatase) ≥ 2 x the upper limit of normal or kidney function tests (creatinine and BUN) ≥ 2 x the upper limit of normal;
- current or past history of seizure disorder;
- a history of head trauma that resulted in neurological sequelae;
- major psychiatric disorder not due to substance abuse (e.g., schizophrenia, bipolar illness but excepting stable major depressive disorder, generalized anxiety disorder, etc.) as assessed by the MINI;
- have a current neurological disorder (e.g., organic brain disease, dementia) or medical condition which would make study compliance difficult or compromise informed consent;
- current ongoing treatment with psychotropic medications (e.g. antidepressants, antipsychotics, antiepileptics, sedative/hypnotics, narcotic analgesics);
- history of suicide attempt(s) in the past 6 months or active suicidal intention or plan (score 4 or 5) in the past month as assessed by the C-SSRS;
- evidence of clinically significant heart disease or hypertension;
- evidence of untreated or unstable serious medical illness including: neuroendocrine, autoimmune, renal, hepatic, or active infectious disease including active tuberculosis infection;
- have HIV infection and currently symptomatic, have a diagnosis of AIDS, or are receiving antiretroviral medication;
- have a medical condition that makes maintaining reliable intravenous access impossible;
- donated blood or plasma within 3 months of inpatient admission;
- use of OAT1 inhibitor (e.g. probenecid, uricosurics, antivirals, nonsteroidal anti-inflammatories, loop diuretics, angiotensin II receptor antagonists, proton pump inhibitors, or statins) or CYP2D6 inducers or inhibitors within 14 days or five half-lives, whichever is longer, from admission;
- currently employed by UCLA or Denovo or a first-degree relative of UCLA or Denovo employee or;
- any other circumstances that, in the opinion of the investigators, would compromise participant safety and/or successful completion of the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pomaglumetad methionil Low + Methamphetamine
Pomaglumetad 40 mg orally twice daily x 9 days with intravenous methamphetamine challenges
|
Tablets twice daily
intravenous methamphetamine
|
Experimental: Pomaglumetad methionil Mid + Methamphetamine
Pomaglumetad 40 mg orally twice daily x 1 day then pomaglumetad 80 mg orally twice daily x 8 days with intravenous methamphetamine challenges
|
Tablets twice daily
intravenous methamphetamine
|
Experimental: Pomaglumetad methionil High + Methamphetamine
Pomaglumetad 40 mg orally twice daily x 1 day then pomaglumetad 160 mg orally twice daily x 8 days with intravenous methamphetamine challenges
|
Tablets twice daily
intravenous methamphetamine
|
Placebo Comparator: Control + Methamphetamine
1-4 placebo tabs orally twice daily x 9 days (to match pomaglumetad dosing in each cohort) with intravenous methamphetamine challenges
|
intravenous methamphetamine
1-4 tablets twice daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood pressure
Time Frame: 0 to 240 minutes after IV methamphetamine
|
Blood pressure following IV methamphetamine during treatment with pomaglumetad or placebo
|
0 to 240 minutes after IV methamphetamine
|
Heart rate
Time Frame: 0 to 240 minutes after IV methamphetamine
|
Heart rate following IV methamphetamine during treatment with pomaglumetad or placebo
|
0 to 240 minutes after IV methamphetamine
|
Rate-pressure product
Time Frame: 0 to 240 minutes after IV methamphetamine
|
Rate-pressure product (heart rate * systolic blood pressure, a measure of myocardial oxygen consumption and workload) following IV methamphetamine during treatment with pomaglumetad or placebo
|
0 to 240 minutes after IV methamphetamine
|
Methamphetamine subjective effects
Time Frame: 0 to 240 minutes after IV methamphetamine
|
Self-reported methamphetamine subjective effects assessed with Drug Effect Questionnaire (DEQ-5) and Methamphetamine-based Questionnaire for Stimulant Urges (MA-QSU) following IV methamphetamine during treatment with pomaglumetad or placebo
|
0 to 240 minutes after IV methamphetamine
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peak methamphetamine concentration
Time Frame: 0 to 48 hours after IV methamphetamine
|
C-max of methamphetamine during treatment with pomaglumetad or placebo
|
0 to 48 hours after IV methamphetamine
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean choices for methamphetamine
Time Frame: on day of methamphetamine infusion
|
Mean choices for methamphetamine during treatment with pomaglumetad or placebo in lab model of methamphetamine self-administration
|
on day of methamphetamine infusion
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Sympathomimetics
- Adrenergic Uptake Inhibitors
- Methamphetamine
Other Study ID Numbers
- R01DA043238 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Methamphetamine Use Disorder
-
Turning PointMonash University; Eastern Health; Deakin UniversityCompletedMethamphetamine Use DisorderAustralia
-
University of NebraskaCompleted
-
University of Colorado, DenverNational Institute on Drug Abuse (NIDA)Not yet recruitingMethamphetamine Use DisorderUnited States
-
Turning PointMonash University; Eastern Health; National Centre for Clinical Research on Emerging...RecruitingMethamphetamine Use DisorderAustralia
-
Shanghai Mental Health CenterWuhan Mental Health Centre; Wuhan Judicial Bureau Hanyang Compulsory Isolated...Active, not recruitingMethamphetamine Use DisorderChina
-
Glenn-Milo SantosNational Institute on Drug Abuse (NIDA)Active, not recruitingMethamphetamine Use DisorderUnited States
-
Craig RushNational Institute on Drug Abuse (NIDA)CompletedMethamphetamine Use DisorderUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)Active, not recruitingMethamphetamine Use Disorder | Cocaine Use Disorder | Cocaine Dependence | Methamphetamine Dependence | Stimulant Use Disorder | Methamphetamine Abuse | Cocaine Abuse | Stimulant Abuse | Stimulant UseUnited States
-
University of Texas Southwestern Medical CenterNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCCompletedMethamphetamine Use DisorderUnited States
-
The University of Texas Health Science Center,...RecruitingMethamphetamine Use DisorderUnited States
Clinical Trials on Pomaglumetad methionil
-
NYU Langone HealthTerminatedPost-traumatic Stress Disorder
-
Eli Lilly and CompanyTerminatedSchizophreniaGermany, Spain, United States, Sweden, Austria, France, Poland, Puerto Rico, Romania, Brazil, Greece
-
Denovo Biopharma LLCTerminatedSchizophreniaUnited States, Mexico, Russian Federation, Puerto Rico, Ukraine
-
Denovo Biopharma LLCCompleted
-
New York State Psychiatric InstituteNational Institute of Mental Health (NIMH)Completed
-
Denovo Biopharma LLCCompletedSchizophreniaItaly, United States, Spain, Israel
-
Denovo Biopharma LLCCompletedSchizophrenic DisordersUnited States
-
New York State Psychiatric InstituteNational Institute of Mental Health (NIMH)Completed
-
Denovo Biopharma LLCCompleted
-
Denovo Biopharma LLCCompletedSchizophreniaUnited States, Mexico, Germany, Russian Federation